Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
The prognosis for untreated renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC TT) is poor, and the only curative treatment option is extirpative surgery. However, radical nephrectomy with IVC thrombectomy is associated with high rates of morbidity and mortality. ...
Clear cell renal cell carcinoma (ccRCC) exhibits considerable heterogeneity, with approximately 25% of localized cases susceptible to relapse, highlighting the...
The data were presented at the 2025 ASCO Genitourinary Cancers Symposium.
Lenvatinib plus pembrolizumab showed activity and a favorable safety profile in nonmetastatic clear cell renal cell carcinoma, per phase 2 study results.
Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination tivozanib and nivolumab in for renal cell carcinoma (RCC) in the TiNivo-2 study, according to a poster presented at the American Society of Clinical Oncology Genitourinary ...
Background: Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of renal cell carcinoma, and immune checkpoint regulator-based immunotherap...
“Taken altogether, the study remains positive for PFS, but not for overall survival,” says Laurence Albiges, MD, PhD.
“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.
Studied in combination with Opdivo, Cabometyx saw RCC patients surviving 11 months longer than sunitinib patients.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.